Thus, it can be assumed that the TIMP-2 and TGF-β1 pathways are not crucial in maintaining and progressing fibrosis in patients after radical breast cancer treatment in the long-term follow-up period of >12 months. This evidence concerns the gene TIMP2 and breast cancer.